The team at Wiggin LLP advises clients across all IP rights, handling SPC appeals, patent disputes, plant breeders’ rights, patent licensing work, and research-related transactions and agreements in the automotive, biotech, electronics and medical devices fields. Sara Ashby leads the offering, which is strengthened by Michael Browne, who is experienced in both contentious and transactional work, and Calum Smyth, whose interests include tech and software mandates. Georgina Hart is another name to note.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
‘This is a leading IP practice with some exceptional practitioners. The lawyers are very experienced in both contentious and non-contentious matters. They are commercially oriented and provide effective solutions to complex legal disputes.’
‘Calum Smyth is a truly excellent patent litigator. He brings to Wiggin LLP an unrivalled breadth of knowledge in law and client management. He shows technical flair and is able to embrace new and complex technical areas, including fintech and software patentability.'
- 'Sara Ashby is a superb team leader and has an enviable record as a litigator in all areas of IP. Sara has a razor-sharp legal brain, but is still very commercial and client-focused. These qualities, together with her determination in litigation to get the best results for her clients, mean that she is in great demand. Sara is able to turn her hand to a range of different subject-matter areas, from patents to trade marks.'
- 'I have no hesitation in recommending Calum Smyth and Sara Ashby and their colleagues in the Wiggin IP team.'
- 'Sara Ashby and Calum Smyth are amongst the most able IP attorneys around.'
Key clients
- Entain
- Permavent
- Sage Group Plc
- Thought Machine Group Limited
- Halozyme
- BPW
Work highlights
Representing a client in patent litigation against Touchlight Genetics.
Represent Halozyme, Inc. in its appeal of a UK Intellectual Property Office decision rejecting applications for SPCs in respect of the combination products (1) trastuzumab and recombinant human hyaluronidase and (2) rituximab and recombinant human hyaluronidase.
Lawyers
Leading partners
The strongest partners in their field, leading on market-leading deals and endorsed by peers and clients alike.
Practice head
Sara Ashby
Other key lawyers
Michael Browne; Calum Smyth; Georgina Hart; Sinclaire Schafer